NBR1 Inhibitors
NBR1 inhibitors comprise a diverse class of pharmacological agents designed to selectively modulate the intricate signaling pathways associated with NBR1 expression and function. The identified chemicals act through various mechanisms to disrupt key cellular processes involved in NBR1 regulation. Notably, the histone deacetylase (HDAC) inhibitor Vorinostat targets epigenetic regulation by inhibiting HDACs, thereby influencing gene expression. By modulating the acetylation status of histones, Vorinostat can impact the transcriptional regulation of genes involved in NBR1 control.
In addition to epigenetic modulation, the AMP-activated protein kinase (AMPK) activator A769662 and the mTOR inhibitor AZD8055 intervene in crucial signaling pathways. A769662 indirectly inhibits NBR1 by activating AMPK and disrupting mTORC1 signaling, which plays a pivotal role in cellular processes such as protein synthesis and cell growth. Meanwhile, AZD8055 directly targets mTOR, exerting an inhibitory effect on downstream signaling events that may influence NBR1-associated cellular responses. These inhibitors, along with others such as BAY 11-7082, Enzalutamide, CCT007093, VX-11e, Y-27632, SP600125, GDC-0941, SB-431542, and UNC-1999, constitute a comprehensive toolkit for researchers aiming to dissect the intricate regulatory networks governing NBR1-mediated cellular functions. By utilizing this array of inhibitors, researchers can systematically investigate the impact of specific pathways on NBR1 expression and elucidate the molecular intricacies underpinning NBR1-associated cellular responses.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid (Vorinostat) is a histone deacetylase (HDAC) inhibitor that modulates gene expression by inhibiting the removal of acetyl groups from histones. This epigenetic modulation can influence cellular processes involved in gene regulation, potentially impacting various signaling pathways. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
A769662 is an AMP-activated protein kinase (AMPK) activator that indirectly inhibits mTORC1, a key regulator of protein synthesis and cell growth. By activating AMPK, A769662 disrupts the mTORC1 signaling pathway, potentially influencing cellular processes associated with protein translation. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of mTOR, a central player in the PI3K/AKT/mTOR signaling pathway. By directly targeting mTOR, AZD8055 inhibits downstream signaling events, potentially affecting processes such as protein synthesis, cell growth, and survival. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an inhibitor of nuclear factor-kappa B (NF-κB) activation. By interfering with the NF-κB signaling pathway, BAY 11-7082 can modulate the expression of genes involved in inflammation, cell survival, and immune responses, potentially impacting various cellular processes. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
MDV3100 is an androgen receptor (AR) antagonist studied in the research of prostate cancer. By inhibiting AR signaling, Enzalutamide disrupts the transcriptional activity of AR, potentially influencing cellular processes related to androgen-dependent growth and survival. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
VX-11e is a selective inhibitor of focal adhesion kinase (FAK), a key player in integrin signaling. By inhibiting FAK, VX-11e can disrupt cellular processes related to cell adhesion, migration, and invasion, potentially influencing signaling pathways involved in cancer progression and metastasis. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK), which plays a role in the regulation of the actin cytoskeleton. By inhibiting ROCK, Y-27632 can potentially impact cellular processes such as cell migration, proliferation, and contractility, influencing signaling pathways involved in these processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK), a member of the mitogen-activated protein kinase (MAPK) family. By inhibiting JNK, SP600125 can modulate cellular processes such as apoptosis, inflammation, and cell differentiation, potentially impacting various signaling pathways. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a key enzyme in the PI3K/AKT signaling pathway. By inhibiting PI3K, GDC-0941 can disrupt downstream signaling events, potentially influencing cellular processes such as cell survival, proliferation, and metabolism. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542 is a selective inhibitor of transforming growth factor-beta (TGF-β) type I receptor (ALK5). By inhibiting ALK5, SB-431542 can modulate TGF-β signaling, potentially impacting cellular processes involved in cell growth, differentiation, and immune responses. | ||||||